LKT Laboratories, Inc.

Voglibose

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID V5725
CAS No. 83480-29-9
Chemical Name (1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol
Synonym Glustat; Basen; AO-128; Vocarb; 3,4-dideoxy-4-((2-hydroxy-1-(hydroxymethyl) ethyl)amino)-2-C-(hydroxymethyl)-D-epi-inositol



Formula $C_{10}H_{21}NO_7$
Formula Wt. 267.28
Melting Point 162 -164 ℃
Purity ≥98%
Solubility

Bulk quanitites available upon request

Product ID	Size
V5725	5 mg
V5725	10 mg
V5725	25 mg
V5725	100 mg

Store Temp Ambient
Ship Temp Ambient

Description Voglibose is an inhibitor of α-glucosidase that exhibits anti-diabetic, anti-hyperglycemic, anti-hyperlipidemic, anti-melanogenic, and cardioprotective benefits. In obese mice, voglibose increases plasma levels of glucagon-like peptide 1 (GLP -1), indirectly decreasing activity of DPP4. Additionally, voglibose decreases expression of intracellular adhesion molecule 1 (ICAM-1) and excretion of C-reactive protein (CRP), also decreasing oxidative stress. In clinical studies, voglibose improves body mass index and hemoglobin A(1c) values and decreases hyperlipidemia and hyperglycemia. Inhibition of α-glucosidase also blocks N-glycan modification of tyrosinase, decreasing levels of tyrosinase and melanin. In several animal models of myocardial ischemia/reperfusion, voglibose upregulates phosphorylated Akt and phosphorylated eNOS expression, decreasing myocardial infarction size; this compound may also activate GLP-1 receptors or open mitochondrial K+ (ATP) channels,

References

Bin BH, Seo J, Yang SH, et al. Novel inhibitory effect of the antidiabetic drug voglibose on melanogenesis. Exp Dermatol. 2013 Aug;22(8):541-6. PMID: 23879813.

Iwasa M, Kobayashi H, Yasuda S, et al. Antidiabetic drug voglibose is protective against ischemia-reperfusion injury through glucagon-like peptide 1 receptors and the phosphoinositide 3-kinase-Akt-endothelial nitric oxide synthase pathway in rabbits. J Cardiovasc Pharmacol. 2010 Jun;55(6):625-34. Erratum in: J Cardiovasc Pharmacol. 2012 Jul;60(1):108. PMID: 20351564.

Kawamori R, Tajima N, Iwamoto Y, et al. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet. 2009 May 9;373(9675):1607-14. PMID: 19395079.

Moritoh Y, Takeuchi K, Hazama M. Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice. J Pharmacol Exp Ther. 2009 May;329(2):669-76. PMID: 19208898.

Satoh N, Shimatsu A, Yamada K, et al. An alpha-glucosidase inhibitor, voglibose, reduces oxidative stress markers and soluble intercellular adhesion molecule 1 in obese type 2 diabetic patients. Metabolism. 2006 Jun;55(6):786-93. PMID: 16713439.